Gilde Healthcare Holding B.V. sold $27K of SI (indirect holdings)

Gilde Healthcare Holding B.V. sold 1,196 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at $22.60 on 2026-08-26.

Original reporting
SEC EDGAR · Gilde Healthcare Holding B.V.
Published Aug 28, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$SI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The modest insider divestiture is unlikely to affect SI stock price; market may view it as routine portfolio rebalancing.

02

Market read

Limited trading relevance; small insider sale provides little actionable insight.

03

What to watch

Potential future dilution or reallocation of capital not evident from the modest transaction.

Relevance 3/10Novelty 2/10Timing: filed Aug 28, 2026

Background

SEC Form 4 filed by Gilde Healthcare Holding B.V. reporting an open‑market sale of 1,196 Shoulder Innovations shares at $22.60 each, total $27,030.

Market effects

Minimal effect on healthcare sector; insider sale size too small to move market.

No discernible impact on regional markets.

Negligible global relevance.

Counterpoint

Despite the tiny sale, a 10% owner reducing stake could hint at upcoming strategic changes.

Key entities

  • Shoulder Innovations, Inc.

    Company whose shares were sold in the Form 4 filing.

  • Gilde Healthcare Holding B.V.

    10% owner of Shoulder Innovations reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.